Trial Profile

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Golidocitinib (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
Indications Follicular lymphoma; Immunoblastic lymphadenopathy; Peripheral T-cell lymphoma
Focus Adverse reactions
Acronyms GOLDEN Study

09 Dec 2025 According to Dizal Media Release, data from the trial were presented at the 67th American Society of Hematology (ASH) Annual Meeting.
09 Dec 2025 Results presented in the Dizal Media Release
04 Nov 2025 According to a Dizal Pharmaceutical media release, data from this trial will be presented at the 67th American Society of Hematology (ASH) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com